These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Mooradian MJ; Sullivan RJ Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423 [TBL] [Abstract][Full Text] [Related]
9. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer. Shevchenko I; Bazhin AV Front Immunol; 2018; 9():1816. PubMed ID: 30131808 [TBL] [Abstract][Full Text] [Related]
10. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). Ascierto PA; Agarwala SS; Botti G; Budillon A; Davies MA; Dummer R; Ernstoff M; Ferrone S; Formenti S; Gajewski TF; Garbe C; Hamid O; Lo RS; Luke JJ; Michielin O; Palmieri G; Zitvogel L; Marincola FM; Masucci G; Caracò C; Thurin M; Puzanov I J Transl Med; 2019 Jul; 17(1):234. PubMed ID: 31331337 [TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Duan J; Wang Y; Jiao S Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347 [TBL] [Abstract][Full Text] [Related]
12. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? Nixon AB; Schalper KA; Jacobs I; Potluri S; Wang IM; Fleener C J Immunother Cancer; 2019 Nov; 7(1):325. PubMed ID: 31775882 [TBL] [Abstract][Full Text] [Related]
13. Role of cell surface proteoglycans in cancer immunotherapy. Espinoza-Sánchez NA; Götte M Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150 [TBL] [Abstract][Full Text] [Related]
14. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade. Wilkinson RW; Leishman AJ Front Immunol; 2018; 9():1082. PubMed ID: 29910800 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
16. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945 [TBL] [Abstract][Full Text] [Related]
17. The importance for immunoregulation for long-term cancer control. Fusi A; Dalgleish A Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411 [TBL] [Abstract][Full Text] [Related]
18. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Patel SA; Minn AJ Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193 [TBL] [Abstract][Full Text] [Related]
19. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Yao H; Wang H; Li C; Fang JY; Xu J Front Immunol; 2018; 9():1774. PubMed ID: 30105035 [TBL] [Abstract][Full Text] [Related]
20. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]